Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group.


Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
07 2020
Historique:
received: 07 05 2019
revised: 07 11 2019
accepted: 27 11 2019
entrez: 9 8 2020
pubmed: 9 8 2020
medline: 23 9 2020
Statut: ppublish

Résumé

This study examines European decision makers' consideration and use of quantitative preference data. The study reviewed quantitative preference data usage in 31 European countries to support marketing authorization, reimbursement, or pricing decisions. Use was defined as: agency guidance on preference data use, sponsor submission of preference data, or decision-maker collection of preference data. The data could be collected from any stakeholder using any method that generated quantitative estimates of preferences. Data were collected through: (1) documentary evidence identified through a literature and regulatory websites review, and via key opinion leader outreach; and (2) a survey of staff working for agencies that support or make healthcare technology decisions. Preference data utilization was identified in 22 countries and at a European level. The most prevalent use (19 countries) was citizen preferences, collected using time-trade off or standard gamble methods to inform health state utility estimation. Preference data was also used to: (1) value other impact on patients, (2) incorporate non-health factors into reimbursement decisions, and (3) estimate opportunity cost. Pilot projects were identified (6 countries and at a European level), with a focus on multi-criteria decision analysis methods and choice-based methods to elicit patient preferences. While quantitative preference data support reimbursement and pricing decisions in most European countries, there was no utilization evidence in European-level marketing authorization decisions. While there are commonalities, a diversity of usage was identified between jurisdictions. Pilots suggest the potential for greater use of preference data, and for alignment between decision makers.

Identifiants

pubmed: 32762984
pii: S1098-3015(20)30091-7
doi: 10.1016/j.jval.2019.11.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

831-841

Subventions

Organisme : AHRQ HHS
ID : K12 HS026370
Pays : United States

Informations de copyright

Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Auteurs

Kevin Marsh (K)

Evidera, London, England, UK. Electronic address: kevin.marsh@evidera.com.

Janine A van Til (JA)

Health Technology and Services Research, University of Twente, Enschede, The Netherlands.

Elizabeth Molsen-David (E)

Scientific and Health Policy Initiatives, ISPOR, Lawrenceville, NJ, USA.

Christine Juhnke (C)

Hochschule Neubrandenburg, Neubrandenburg, Germany.

Natalia Hawken (N)

Modus Outcomes, Amsterdam, The Netherlands.

Elisabeth M Oehrlein (EM)

National Health Council, Washington, DC, USA.

Y Christy Choi (YC)

University of Minnesota College of Pharmacy, Minneapolis, Minnesota.

Alejandra Duenas (A)

ICN Business School, Nancy, France.

Wolfgang Greiner (W)

Department of Health Economics, Bielefeld University, Bielefeld, Germany.

Kara Haas (K)

Cerenovus, New Brunswick, NJ, USA.

Mickael Hiligsmann (M)

Department of Health Services Research, Maastricht University, Maastricht, The Netherlands.

Kimberley S Hockley (KS)

Imperial Clinical Trials Unit, Imperial College London, London, England, UK.

Ilya Ivlev (I)

Center for Health Research, Kaiser Permanente, Portland, OR, USA.

Frank Liu (F)

Merck & Co, Kenilworth, NJ, USA.

Jan Ostermann (J)

Department of Health Services Policy and Management, University of South Carolina, Columbia, SC, USA.

Thomas Poder (T)

CIUSSS de l'Estrie-CHUS, Sherbrooke, QC, Canada.

Jiat L Poon (JL)

Eli Lilly and Company, Indianapolis, IN, USA.

Axel Muehlbacher (A)

Hochschule Neubrandenburg, Neubrandenburg, Germany; Department of Population Health Sciences, Duke University, Durham, NC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH